Physician profile
Leanne Knowles
NPI 1447635305
$1,722.41
in general payments reported to CMS, 2019-2025
35 companies · $618 in 2025
The $618 reported for 2025 was more than what 79% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $205 · 2022: $191 · 2023: $464 · 2024: $245 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,327.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $226.74 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $148.34 | 2022-2025 | |
| Glaxosmithkline, LLC. | $139.91 | 2023 | Arexvy, Shingrix |
| Novo Nordisk INC | $119.57 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $94.22 | 2021-2023 | |
| Astrazeneca Pharmaceuticals Lp | $84.11 | 2022-2024 | Airsupra, Farxiga |
| Regeneron Healthcare Solutions, INC. | $82.06 | 2025 | Libtayo |
| Otsuka America Pharmaceutical, INC. | $66.71 | 2023-2024 | Rexulti |
| Daiichi Sankyo INC. | $61.20 | 2021-2025 | Enhertu |
| Tersera Therapeutics LLC | $59.49 | 2025 | Zoladex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.34 | 2021-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $52.82 | 2021-2023 | |
| Sobi, INC | $44.50 | 2025 | |
| Jazz Pharmaceuticals INC. | $43.79 | 2025 | |
| Incyte Corporation | $39.83 | 2025 | Jakafi, Zynyz, Monjuvi |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $36.92 | 2025 | Clonoseq |
| Merck Sharp & Dohme LLC | $36.71 | 2025 | Keytruda, Lynparza |
| Exact Sciences Corporation | $27.00 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $25.16 | 2022-2023 | Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.06 | 2024 | Caplyta |
| Medtronic, INC. | $23.36 | 2023 | Minimed 780g |
| Takeda Pharmaceuticals U.S.A., INC. | $20.08 | 2021 | |
| Csl Behring | $19.74 | 2025 | Hizentra |
| Amgen INC. | $19.68 | 2023 | Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $18.36 | 2022 | |
| Eisai INC. | $18.27 | 2025 | |
| Tolmar, INC. | $17.22 | 2025 | Eligard |
| Deciphera Pharmaceuticals INC. | $16.79 | 2025 | Romvimza, Qinlock |
| Sumitomo Pharma America, INC. | $15.73 | 2025 | Orgovyx |
| Astellas Pharma US INC | $15.67 | 2024 | Veozah |
| Janssen Pharmaceuticals, INC | $15.63 | 2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $15.51 | 2024 | Camzyos |
| Corium, LLC | $13.41 | 2023 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $12.92 | 2022 | |
| Idorsia Pharmaceuticals US INC | $12.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leanne Knowles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.